Europe Human Fibrin Glue (HFG) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE HUMAN FIBRIN GLUE (HFG) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PACKAGE FORM LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 INDUSTRY INSIGHTS
6 REGULATORY ANALYSIS
6.1.1 REGULATION IN U.S.
6.1.2 REGULATION IN EUROPE
6.1.3 REGULATION IN AUSTRALIA
6.1.4 REGULATION IN CANADA
6.1.5 REGULATION IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN TECHNOLOGICAL ADVANCEMENT
7.1.2 INCREASING SURGICAL PROCEDURES
7.1.3 ADVANTAGES OF HUMAN FIBRIN GLUE
7.1.4 INCREASE IN THE GERIATRIC POPULATION
7.1.5 SUPERIORITY OF FIBRIN SEALANTS, OVER LIMITATIONS OF CONVENTIONAL METHODS
7.2 RESTRAINTS
7.2.1 STRINGENT RULES & REGULATORY
7.2.2 HIGH COST OF PRODUCTS
7.2.3 RISK OF VIRAL INFECTIONS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN PREVALENCE OF CHRONIC DISORDERS
7.3.2 RISE IN MINIMALLY INVASIVE SURGERIES
7.3.3 RISING PLASTIC SURGERIES
7.4 CHALLENGES
7.4.1 COMPLICATION RELATED TO USE OF HUMAN FIBRIN GLUE
7.4.2 LACK OF SKILLED PROFESSIONALS
7.4.3 DECREASED SURGICAL PROCEDURES DUE TO COVID-19
8 IMPACT OF COVID-19 ON EUROPE HUMAN FIBRIN GLUE (HFG) MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON SUPPLY CHAIN
8.3 IMPACT ON DEMAND
8.4 CONCLUSION
9 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY PACKAGE FORM
9.1 OVERVIEW
9.2 LIQUID
9.2.1 1-2 ML
9.2.2 7-10 ML
9.2.3 3-4 ML
9.2.4 5-6 ML
9.3 PATCH
9.4 OTHERS
10 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALTY CLINICS
10.4 AMBULATORY CARE CENTER
10.5 OTHERS
11 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 RETAIL SALES
12 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 WOUND MANAGEMENT
12.3 BURN BLEEDING
12.4 PLASTIC SURGERY
12.5 GENERAL SURGERY
12.6 VASCULAR SURGERIES
12.7 LACERATIONS OF LIVER AND SPLEEN
12.8 CARDIAC SURGERY
12.9 PULMONARY SURGERY
12.10 ORTHOPEDIC SURGERIES
12.11 NEUROSURGERY
12.12 OTHERS
13 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 U.K.
13.1.3 FRANCE
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 SWITZERLAND
13.1.7 RUSSIA
13.1.8 NETHERLANDS
13.1.9 TURKEY
13.1.10 BELGIUM
13.1.11 REST OF EUROPE
14 EUROPE HUMAN FIBRIN GLUE (HFG) MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 CSL LIMITED
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 JOHNSON & JOHNSON SERVICES, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 BAXTER
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 HUALAN BIOLOGICAL ENGINEERING, ING
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 SHANGHAI RAAS
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 CORZA HEALTH
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 MARQUEE BIOSURGICAL
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS